Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Danforth Center, Vermillion, and More


Bradley Evans has joined the Donald Danforth Plant Science Center as director of its Proteomics and Mass Spectrometry facility.

Evans formerly was at the Institute for Genomic Biology at the University of Illinois Urbana-Champaign, where he was in charge of administration of the scientific core and providing access to instrumentation, experimental design, training, and sample analysis.

Vermillion's board of directors has promoted Eric Schoen to be VP of finance, effective immediately.

Schoen will continue to serve in his current post as company chief accounting officer, which he has held since 2011.

Atossa Genetics said this week that Peter Carbonaro has joined the firm as senior VP of operations, a newly created position.

Carbonaro formerly was VP of operations at Ondine Biomedical, and he spent about five years each at Gilead Sciences and Corus Pharma, which was acquired by Gilead.

He launched his career at Roche Diagnostic Systems, where he was production manager, senior group leader, and associate scientist.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.